Oral small-molecule GLP-1 receptor agonist
Orforglipron
The Foundayo label gives orforglipron's elimination half-life as approximately 29 to 49 hours after an oral dose; the app lists 39 hours.1
Orforglipron after one dose: 50% at ~39 h, 25% at 78 h, 12.5% at 117 h.
Drawn from the half-life in the app's model, ~39 h. The model's figures
- Compound
- Orforglipron
- Symbol
- ORF
- Family
- GLP-1 and incretin
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Orforglipron is an oral GLP-1 receptor agonist made by Eli Lilly and Company and sold in the United States as Foundayo tablets.1 The ATTAIN-1 paper calls it a "small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist".2 The US label gives 2026 as the initial approval year.1 The label's single listed use is, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition.1 Under limitations of use, the label states that "Concomitant use with another GLP-1 receptor agonist is not recommended".1
The app grades the evidence for orforglipron as strong; the phase 2, ATTAIN-1, ACHIEVE-1 and ATTAIN-2 trials described below were funded or supported by Eli Lilly, and the phase 1a and bioavailability records state no funding source.
How it works
Sources in this part
The label states that the drug "binds to and activates the human GLP-1 receptor".1 It adds that "GLP-1 receptors are present in brain regions that regulate appetite", and that "In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake".1 The label also states that it "delays gastric emptying" and that "The delay is largest after the first dose and diminishes over time".1
Sloop and colleagues, Lilly Research Laboratories, Science Translational Medicine, 2024, studied the receptor pharmacology in cells and animals, not in people.6 In binding experiments they reported that "orforglipron is a high-affinity [inhibition constant (Ki) = 1 nM], selective ligand of the human GLP-1R".6 In signal transduction assays, "orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment".6 In mice expressing the human receptor, they report that "low GLP-1R occupancy by orforglipron is sufficient to yield a full biological response".6 The label notes that "Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~39 h
- Bioavailability
- 77%
- Typical dose
- 0.8–17.2 mg/day
- Route
- Oral
- Time to peak
- ~6 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~39 h | Elimination half-life of approximately 29 to 49 hours after an oral dose on the label; mean t1/2 of 24.6 to 35.3 hours after a single dose of 0.3 to 6 mg and 48.1 to 67.5 hours on Day 28 of daily dosing at 2 to 24 mg in healthy participants in a phase 1a study by Eli Lilly authors1,7 |
| Time to peak | ~6 h | Maximum concentration reached 4 to 8 hours post dose on the label1 |
| Bioavailability | 77% | Geometric mean absolute bioavailability of 77% after a 0.8 mg dose on the label; mean absolute oral bioavailability of 79.1% ± 16.8% in 10 fasting healthy adults given a 1-mg oral capsule and an intravenous microdose of labelled drug (Morse and colleagues, Eli Lilly authors)1,8 |
| Volume of distribution | 285 L | Mean steady-state volume of distribution of approximately 285 L following intravenous dosing in healthy subjects on the label1 |
The label adds that "The mean systemic clearance of orforglipron is 7.15 L/hour" and that "Orforglipron plasma protein binding is greater than 99%".1 It states that "Steady state exposure is achieved after approximately 1 week of once daily administration".1 On food, the label reports that "No clinically relevant food effect on orforglipron exposure was observed".1 Except in the food effect study, the label says its data were generated with an investigational formulation.1 On metabolism, the label states that orforglipron "is metabolized primarily via hepatic CYP3A4 to several oxidative metabolites", with 87% of a single 2.5 mg oral dose recovered in feces and less than 1% in urine.1 Morse and colleagues list Eli Lilly and Company as the affiliation of six of the seven authors, and the record does not state a funding source.8 For hepatic impairment, the label reports that "Orforglipron AUC(0-∞) increased by 1.7-fold and 4.6-fold in patients with moderate and severe hepatic impairment, respectively, compared to subjects with normal hepatic function".1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 39 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Pratt and colleagues, phase 1a, Diabetes, Obesity and Metabolism 20237 | Double-blind, placebo-controlled, single and multiple ascending dose; authors at Eli Lilly7 | 92 healthy adults aged 18 to 65 years with BMI 20 to 40 kg/m2 (32 in Part A, 60 in Part B)7 | Part A single doses of 0.3 to 6 mg; Part B 4 weeks of daily doses escalating weekly to final targets of 2 to 24 mg7 | Gastrointestinal adverse events were most common; weight fell by up to 5.4 kg against 2.4 kg with placebo after 4 weeks; fasting glucose decreased; gastric emptying delayed on Day 287 |
| Frias and colleagues, phase 2, Lancet 20234 | 26-week, double-blind, randomised, multicentre; placebo and dulaglutide comparators; funded by Eli Lilly4 | 383 adults with type 2 diabetes randomly assigned; 352 (92%) completed the study and 303 (79%) completed 26 weeks of treatment4 | Orforglipron 3, 12, 24, 36 or 45 mg once per day against placebo or dulaglutide 1.5 mg once per week4 | HbA1c change up to -2.10% (-1.67% placebo adjusted) against -0.43% with placebo and -1.10% with dulaglutide, in an efficacy analysis that excluded data after permanent discontinuation of study drug or initiation of rescue medication; adverse events in 61.8% to 88.9% with orforglipron, 61.8% with placebo, 56.0% with dulaglutide, the majority gastrointestinal (44.1% to 70.4% with orforglipron, 18.2% with placebo, 34.0% with dulaglutide)4 |
| Wharton and colleagues, ATTAIN-1, New England Journal of Medicine 20252 | Phase 3, multinational, randomised, double-blind, placebo-controlled; funded by Eli Lilly, six named authors at Eli Lilly2 | 3127 adults with obesity without diabetes2 | Orforglipron 6, 12 or 36 mg once daily or placebo (3:3:3:4), 72 weeks2 | Weight change -7.5%, -8.4% and -11.2% against -2.1% with placebo (treatment-regimen estimand); adverse-event discontinuation 5.3 to 10.3% against 2.7%2 |
| Rosenstock and colleagues, ACHIEVE-1, New England Journal of Medicine 20253 | Phase 3, double-blind, placebo-controlled; supported by Eli Lilly, nine named authors at Eli Lilly3 | 559 adults with type 2 diabetes treated with diet and exercise only, HbA1c 7.0% to 9.5%, BMI of at least 23.03 | Orforglipron 3, 12 or 36 mg once daily or placebo (1:1:1:1), 40 weeks3 | HbA1c change -1.24, -1.47 and -1.48 percentage points against -0.41 with placebo; weight change -4.5%, -5.8%, -7.6% against -1.7%; adverse-event discontinuation 4.4 to 7.8% against 1.4%3 |
| Horn and colleagues, ATTAIN-2, Lancet 20265 | 72-week, phase 3, double-blind, placebo-controlled, 136 sites in ten countries; funded by Eli Lilly5 | 1613 adults with BMI of 27 kg/m2 or higher and type 2 diabetes (HbA1c 7-10%)5 | Orforglipron 6, 12 or 36 mg once daily or placebo (1:1:1:2), 72 weeks5 | Weight change -5.1%, -7.0% and -9.6% against -2.5% with placebo (treatment-regimen estimand); discontinuation for adverse events 6.1 to 9.9% against 4.1%; ten deaths (six orforglipron, four placebo)5 |
Deeper analysis: ATTAIN-1
Wharton and colleagues (affiliations including McMaster University, Weill Cornell Medicine and Eli Lilly) reported ATTAIN-1 in the New England Journal of Medicine in 2025.2 The design was "phase 3, multinational, randomized, double-blind", with once-daily orforglipron at 6 mg, 12 mg or 36 mg against placebo, assigned 3:3:3:4, "as an adjunct to healthy diet and physical activity for 72 weeks".2 All 3127 randomised participants had obesity without diabetes mellitus.2 The primary end point was "the percent change in body weight from baseline to week 72, as assessed according to the treatment-regimen estimand in the intention-to-treat population".2 The mean change was -7.5% (95% CI -8.2 to -6.8) with 6 mg, -8.4% (95% CI -9.1 to -7.7) with 12 mg and -11.2% (95% CI -12.0 to -10.4) with 36 mg, against -2.1% (95% CI -2.8 to -1.4) with placebo, with P<0.001 for all comparisons with placebo.2 Among other measures, "Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo".2 Adverse events led to discontinuation in 5.3 to 10.3% of participants in the orforglipron groups and 2.7% of those on placebo, and "The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate".2 The registry entry lists Eli Lilly and Company as lead sponsor and shows a status of active, not recruiting, with an extension in which "Participants with prediabetes will continue in the extension for another 2 years".9 The registry's adverse event groups list one death among 948 participants on placebo, one among 723 on 6 mg, one among 724 on 12 mg and none among 728 on 36 mg, with serious adverse events in 46, 40, 39 and 28 participants respectively.9 The label describes the same registry-numbered trial as Trial 1, with doses of 5.5 mg, 9 mg and 17.2 mg, and states that "patients with type 2 diabetes were excluded".1 The label reports that trial drug was discontinued in 22%, 22% and 24% of the 5.5 mg, 9 mg and 17.2 mg groups against 30% on placebo, and that the week 72 body weight endpoint was missing for 24%, 16%, 14% and 15% of those randomised to placebo, 5.5 mg, 9 mg and 17.2 mg.1 The trial was "Funded by Eli Lilly", and the affiliation list places six of the 13 named authors (Stefanski, Zhou, Macpherson, Allen, Ahmad and Klise) at Eli Lilly, Indianapolis.2 The authors' own statement of limitations and their individual disclosures are not reproduced in the sources cited here, because the full text of this paper is not in PubMed Central.
Deeper analysis: ACHIEVE-1
Rosenstock and colleagues (Velocity Clinical Research, Dallas, and Eli Lilly) reported ACHIEVE-1 in the New England Journal of Medicine in 2025.3 It was a phase 3, double-blind, placebo-controlled trial in which participants were assigned 1:1:1:1 to orforglipron 3 mg, 12 mg or 36 mg or placebo once daily for 40 weeks.3 Participants had "type 2 diabetes treated only with diet and exercise", a glycated hemoglobin level of 7.0% to 9.5% and a body-mass index of at least 23.0; 559 were randomised and baseline HbA1c averaged 8.0%.3 The primary end point was the change in HbA1c to week 40; a key secondary end point was percent change in body weight.3 HbA1c changed by -1.24, -1.47 and -1.48 percentage points with 3 mg, 12 mg and 36 mg, against -0.41 with placebo.3 The estimated mean differences from placebo were -0.83 (95% CI -1.10 to -0.56), -1.06 (95% CI -1.33 to -0.79) and -1.07 (95% CI -1.33 to -0.81) percentage points, with P<0.001 for all comparisons.3 Weight changed by -4.5%, -5.8% and -7.6% against -1.7% with placebo.3 The authors report that "The most common adverse events were mild-to-moderate gastrointestinal events, most of which occurred during dose escalation", that "No episodes of severe hypoglycemia were reported", and that permanent discontinuation due to adverse events occurred in 4.4 to 7.8% on orforglipron and 1.4% on placebo.3 The registry entry lists Eli Lilly and Company as lead sponsor and a completed status.10 Its adverse event groups list one death among 138 on placebo, two among 143 on 3 mg, one among 137 on 12 mg and none among 141 on 36 mg, with serious adverse events in 5, 8, 7 and 4 participants respectively.10 The trial was "Supported by Eli Lilly", and the affiliation list places nine of the 12 named authors at Eli Lilly, Indianapolis.3 As with ATTAIN-1, the authors' own statement of limitations is not reproduced in the sources cited here, because the full text is not in PubMed Central.
Deeper analysis: ATTAIN-2
Horn and colleagues (University of Texas McGovern Medical School, Pennington Biomedical Research Center and others, with Eli Lilly authors) reported ATTAIN-2 in the Lancet in 2026.5 Of 2859 screened, 1613 were randomly assigned to orforglipron 6 mg (n=329), 12 mg (n=332), 36 mg (n=322) or placebo (n=630), and 1444 (89.5%) completed the study.5 Weight changed by -5.1% with 6 mg, -7.0% with 12 mg and -9.6% with 36 mg, against -2.5% with placebo.5 Discontinuations due to adverse events were "higher for orforglipron (6·1-9·9%) versus placebo (4·1%)", and "Ten deaths were reported during the study: six with orforglipron and four with placebo".5 The investigators "deemed all deaths unrelated to the study treatment, except for one case in the placebo group and one case in the 12 mg orforglipron group", and for the orforglipron case "no treatment-related association was reported".5 The trial was funded by Eli Lilly and Company; six authors are listed as employees and stockholders of Eli Lilly, and the first author reports consulting fees from Eli Lilly among other companies.5 The authors' own statement of limitations is not reproduced in the sources cited here.
The phase 2 trial in type 2 diabetes
Frias and colleagues (Velocity Clinical Research and Eli Lilly) reported a 26-week phase 2 trial in the Lancet in 2023, funded by Eli Lilly and Company.4 Three participants on orforglipron and one on dulaglutide had clinically significant hypoglycaemia, none had severe hypoglycaemia, and one death occurred in the placebo group that "was not related to study treatment".4 The conflict-of-interest statement lists seven authors as employees and shareholders of Eli Lilly and the first author as a recipient of research funding, consulting fees and speaker fees from Eli Lilly among other companies.4
Doses reported in studies and on labels
The app's typical dose range of 0.8 to 17.2 mg per day matches the label's lowest and highest tablet strengths.1 The label dosing steps are given in the table; the label says its efficacy data come from the investigational orforglipron formulation and are "shown as equivalent dosages of once daily FOUNDAYO".1
| Source and setting | Dose and route | Comparator | Duration and n | Reference |
|---|---|---|---|---|
| US label, adults with obesity or overweight | Starting dosage of 0.8 mg orally once daily; at least 30 days, then 2.5 mg; at least 30 days, then 5.5 mg; further steps of 9, 14.5 or 17.2 mg after at least 30 days each; maximum 17.2 mg once daily | None (label dosing) | Steps of at least 30 days; no n | Foundayo label1 |
| US label, with a strong CYP3A4 inhibitor | Maximum 9 mg once daily, oral | None (label dosing) | No n | Foundayo label1 |
| Label Trial 1 (ATTAIN-1, NCT05869903), adults without type 2 diabetes | 5.5, 9 or 17.2 mg once daily, oral | Placebo (3:3:3:4); treatment effect at week 72 | 72 weeks; 3,127 enrolled | Foundayo label1 |
| Label Trial 2 (ATTAIN-2, NCT05872620), adults with type 2 diabetes | 5.5, 9 or 17.2 mg once daily, oral | Placebo (1:1:1:2); treatment effect at week 72 | 72 weeks; 1,613 enrolled | Foundayo label1 |
| ATTAIN-1, adults with obesity without diabetes | 6, 12 or 36 mg once daily, oral; 36 mg reached at week 20 | Placebo; treatment-regimen estimand | 72 weeks; 3127 | Wharton and colleagues; registry2,9 |
| ACHIEVE-1, adults with early type 2 diabetes | 3, 12 or 36 mg once daily, oral | Placebo | 40 weeks; 559 | Rosenstock and colleagues; registry3,10 |
| ATTAIN-2, adults with type 2 diabetes | 6, 12 or 36 mg once daily, oral | Placebo; treatment-regimen estimand | 72 weeks; 1613 | Horn and colleagues5 |
| Phase 2, adults with type 2 diabetes | 3 to 45 mg once per day, oral | Placebo; dulaglutide 1.5 mg weekly | 26 weeks; 383 | Frias and colleagues4 |
| Phase 1a, healthy adults | Single oral doses of 0.3 to 6 mg; 4 weeks daily, final 2 to 24 mg | Placebo | Single dose, then 4 weeks; 92 | Pratt and colleagues7 |
| Bioavailability study, healthy adults | 1 mg oral capsule plus intravenous microdose | Within-person | Single dose; 10 | Morse and colleagues8 |
The label describes administration as "once daily, with or without food", with tablets swallowed whole and not broken, crushed or chewed.1 On interactions, the label states that "Use of FOUNDAYO with simvastatin increased exposure of the active metabolite simvastatin acid two-fold", and that moderate and strong CYP3A4 inducers decrease orforglipron exposure.1
Side effects reported
Sources in this part
The label draws its adverse reaction data from "a pool of two randomized, double-blind, placebo-controlled trials that included 3155 adult patients with obesity or overweight treated with FOUNDAYO once daily for up to 72 weeks".1 In that pool, 8% of patients on the drug (5.5 mg, 6%; 9 mg, 9%; and 17.2 mg, 10%) permanently discontinued because of adverse reactions, against 3% on placebo.1 Gastrointestinal adverse reactions occurred in 60% (5.5 mg), 68% (9 mg) and 69% (17.2 mg) against 37% on placebo, and led to discontinuation in 3%, 6% and 6% against 0.7%.1 Of those reporting such reactions, "60%, 36%, and 4% reported mild or moderate or severe adverse reactions, respectively", and "The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time".1 Other label figures in the same pool include acute pancreatitis confirmed by adjudication in 6 treated patients (0.14 per 100 years of exposure) against 1 placebo patient (0.04), acute kidney injury in 0.2% against 0.05%, hypotension in 2% against 0.5%, and tachycardia in 3% against 0.9%.1 Hypoglycemia in the trial of adults with type 2 diabetes was "reported in 2% of FOUNDAYO-treated patients versus 0.2% of placebo-treated patients", and 7% of those also taking a sulfonylurea reported it against 0.5% of those not taking one.1 The boxed warning states that rodent thyroid C-cell tumors have been seen with products that are pharmacologically active in rats and mice, that orforglipron "did not produce tumors in rodents", and that "the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined".1 The label states that the drug "is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)".1 The label also states that the drug "is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C)" and, on pregnancy, that "There are no adequate and well-controlled studies of FOUNDAYO during pregnancy".1
Bloodwork and markers
Sources in this part
The app lists blood glucose, HbA1c and body weight as markers to monitor. In ACHIEVE-1, HbA1c was the primary end point and body weight a key secondary end point, and "The mean glycated hemoglobin level at week 40 was 6.5 to 6.7% with orforglipron".3 The label states that "Monitor renal function in patients reporting adverse reactions that could lead to volume depletion".1 On thyroid testing, the label states that "Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO".1
Regulatory and anti-doping status
Sources in this part
The US label gives 2026 as the initial US approval year, lists Eli Lilly and Company, and carries a boxed warning on thyroid C-cell tumors.1 The label lists contraindications for a personal or family history of medullary thyroid carcinoma or MEN 2, and for known serious hypersensitivity to orforglipron or any of its excipients.1 The text of the World Anti-Doping Agency's 2026 Prohibited List that was searched does not name orforglipron or GLP-1 receptor agonists.11 The sources cited here include no regulator's document other than the US label.
Storage and handling
Sources in this part
What is not known
The label states that its efficacy data come from an investigational formulation of orforglipron, while its tablets are 0.8 to 17.2 mg, and the label says only that these data are "shown as equivalent dosages"; ATTAIN-1 reports doses of 6, 12 and 36 mg.1,2 The app's half-life of 39 hours falls inside the label's 29 to 49 hour range, while the phase 1a study in healthy participants reported a mean t1/2 of 24.6 to 35.3 hours after single doses and 48.1 to 67.5 hours on Day 28 of daily dosing.1,7 The weight-management trials summarised here ran 72 weeks, and the ATTAIN-1 registry entry states an extension of another 2 years for participants with prediabetes, with no results in the sources cited here.9 PubMed returned 167 records for orforglipron, including trials against oral semaglutide (ACHIEVE-3) and dapagliflozin (ACHIEVE-2) that are not summarised here.
Frequently asked questions
What is the half-life of orforglipron?
How long does orforglipron take to reach its peak level?
The label gives the time to maximum concentration as 4 to 8 hours post dose, and the app lists about 6 hours.1
What is the bioavailability of orforglipron?
Is orforglipron a peptide?
The ATTAIN-1 paper describes orforglipron as a small-molecule, nonpeptide oral GLP-1 receptor agonist.2
Is orforglipron FDA approved?
The US label for Foundayo (orforglipron) gives 2026 as the initial US approval year.1
Is orforglipron banned by WADA?
The 2026 WADA Prohibited List text that was searched does not name orforglipron or GLP-1 receptor agonists.11
Does orforglipron have a boxed warning?
What were the main side effects of orforglipron in trials?
Gastrointestinal reactions were the most common in the label's pool of two placebo-controlled trials, occurring in 60% (5.5 mg), 68% (9 mg) and 69% (17.2 mg) against 37% on placebo.1 In that pool, 8% of treated patients and 3% of those on placebo permanently discontinued because of adverse reactions.1
What weight change was reported in the ATTAIN-1 trial?
In ATTAIN-1, the mean change in body weight at week 72 (treatment-regimen estimand) was -7.5% with 6 mg, -8.4% with 12 mg and -11.2% with 36 mg of orforglipron, against -2.1% with placebo, in 3127 adults with obesity without diabetes.2 Adverse events led to discontinuation in 5.3 to 10.3% of the orforglipron groups and 2.7% of the placebo group, and the trial was funded by Eli Lilly.2
Guides, tools and comparisons
- How to take orforglipronA guide that answers a question on this compound.
- Oral semaglutide vs orforglipronA side-by-side with another compound.
- Previous in GLP-1 and incretin: Oral SemaglutideThe compound before this one in the class.
- Next in GLP-1 and incretin: RetatrutideThe compound after this one in the class.
References
- Eli Lilly and Company. Foundayo (orforglipron) tablets, for oral use. US prescribing information, DailyMed record version 10, 13 August 2026. DailyMed label
- Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. PMID 40960239
- Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med 2025;393:1065-1076. PMID 40544435
- Frias JP, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet 2023;402:472-483. PMID 37369232
- Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet 2026;406:2927-2944. PMID 41275875
- Sloop KW, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med 2024;16:eadp5765. PMID 39693407
- Pratt E, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab 2023;25:2634-2641. PMID 37344954
- Morse BL, et al. Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clin Pharmacol Drug Dev 2026;15:e1594. PMID 40888509
- ClinicalTrials.gov. NCT05869903. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). Registry entry with posted results. NCT05869903
- ClinicalTrials.gov. NCT05971940. A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (ACHIEVE-1). Registry entry with posted results. NCT05971940
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list